Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results

TLDR Eli Lilly stock gains 0.62% as new Phase 3b findings highlight treatment gains. Combined therapy changes 482 proteins versus 140 with Taltz alone by Week 36. Gene activity shifts span 467 genes with both drugs, versus 16 on Taltz alone. Taltz and Zepbound deliver improved skin clearance and weight loss at Week 36. Researchers [...]

The post Eli Lilly and Company (LLY) Stock: Rises as Taltz and Zepbound Show Promising Results appeared first on Blockonomi.